why choose us

First received: November 18, 2024

Clinical Trial: Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Thyroid Cancer

Study Type: INTERVENTIONAL


Official Title: Clinical Study of Aprepitant and Ondansetron Monotherapy or Combination in the Treatment of Postoperative Nausea and Vomiting in Thyroid Carcinoma

Brief Summary: The vast majority of patients treated prophylactically with "first-line" antiemetics in the 5-hydroxytryptamine (5-HT3) receptor antagonist class still have significant PONV.Combination therapies with different pharmacologic bases have the potential to reduce the incidence of PONV.This study is a multicenter, three-arm, prospective study to evaluate the efficacy and safety of aprepitant and ondansetron, monotherapy or in combination, in the prevention of nausea and vomiting after surgery for thyroid…

Read more